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cation utilization and overall health care service use.
METHODS: A prospective longitudinal cohort study em-
ploying robust multiple regression analyses was con-
ducted over a 2-year post-enrollment period in 762 man-
aged care enrolled diabetic older adults, for whom complete
prescription refill data were available. Patients completed
a comprehensive health risk screen measuring self-re-
ported health perception, falls, lifestyle, depressive symp-
tomatology, and pre-enrollment health care service use at
time of enrollment in the plan. We used the medication
possession ratio and total annual health care charges as
measures of post-enrollment antidiabetic medication and
health care service use. RESULTS: We found that in this
population, annual medication possession rates were
nearly 57% for oral hypoglycemics, as compared to ap-
proximately 40% for both insulin as well as insulin sensi-
tizers. Among antidiabetic medications, only insulin pos-
session decreased across time (P  0.05). Older adults
with increased number of diabetic medications, as well as
reporting to have had falls under utilized all antidiabetic
medications (P  0.05). Patients with increased age and
comorbidity under utilized insulin sensitizers (P  0.001).
Self-reported health status was predictive of total health
care service utilization in this population, but not antidia-
betic medication use. After controlling for the significant
effects of health status, comorbidity severity, and number
of medications, a 10% increase in the use of oral hy-
poglycemics was associated with a 3.5% decrease in total
annual non-prescription related health care charges (P 
0.001). CONCLUSION: There seem to be significant dif-
ferences in utilization patterns of different antidiabetic
medications in this older adult population, with a clear
decrease in health care service use associated with in-
creased utilization of oral hypoglycemics. Improving medi-
cation adherence could potentially reduce avoidable med-
ical costs in similar populations.
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OBJECTIVE: To assess the cost-effectiveness of a new
human dermal replacement (Dermagraft–D) compared with
current practice (CP). METHODS: A Markov model was
developed, to simulate the health status of a cohort of
100 patients with a diabetic foot ulcer, during 52 weeks.
The health states considered are: healed, same site recur-
rence, unhealed not infected, cellulitis, osteomyelitis, am-
putation and death. The set of transition probabilities is
derived directly from the US clinical trial. The costs of
each health state were estimated by a Delphi panel of dia-
betologists (direct costs only in a societal perspective).
RESULTS: The total number or ulcers healed is first ul-
cers healed (D: 76,38; median time to heal—MTH: 14–
15 weeks vs CP: 69,35, MTH: 28–29 weeks) plus recur-
rences which are subsequently healed within the 52-week
period (D: 25,24; MTH 3–4 weeks; CP: 14,29 MTH: 5–6
weeks) are significantly different. The average expected
cost per patient (C/E) with CP for the 52 weeks period
considered is 47,418 French Francs (FF) vs 54,384 FF for
D group (including 18.200 FF for D treatment and
36,184 FF of conventional treatment). Because D heals
more ulcers, the average cost per ulcer healed is lower
(53,522 FF vs 56,687 FF). The incremental cost-effective-
ness ratio of D (C/E) equals 387.84 FF. CONCLU-
SION: Human dermal replacement is cost-effective be-
cause it offers an opportunity to heal ulcers for less than
the price that is already paid by the collectivity, using
standard practice (56,687 FF).
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OBJECTIVE: The CODE-2 study provided costs for pa-
tients with diabetes mellitus type 2 in Germany. The aim
of this analysis is to assess the accuracy of these esti-
mates. METHODS: The German arm of CODE-2 was
based on a representative sample of 809 diabetic patients.
Treatment strategies, resource use and costs were investi-
gated for the year 1998. Patients were grouped in 5 strata
based on their complication status, which was assumed
to be the main cost factor. Rare cost driver groups were
over-represented in order to obtain higher accuracy of es-
timates. For extrapolation on a population level, the re-
sults were weighted according to real prevalence data on
complications estimated in a pre-study. Results were cal-
culated as a weighted average from the mean in each stra-
tum. Because the degree of precision of these estimates
was not measurable with the usual statistical methods,
bootstrap estimates were computed for lower and upper
bounds of 95% confidence intervals taking 10,000 inde-
pendent bootstrap samples. RESULTS: Bootstrap esti-
mates were stable after 10,000 replicate samples. CON-
CLUSION: Bootstrap confidence intervals show a
remarkable accuracy of estimations performed in this
study. So combination of a weighted stratification by cost
factor followed by bootstrapping estimation is an appro-
priate method for analysing the average of highly vari-
able parameters such as costs of diabetes.
